MCID: PPL002
MIFTS: 51

Papillary Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Carcinoma

MalaCards integrated aliases for Papillary Carcinoma:

Name: Papillary Carcinoma 12 15
Carcinoma, Papillary 44 73
Carcinoma Papillary 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3113
MeSH 44 D002291
NCIt 50 C2927
SNOMED-CT 68 25910003
UMLS 73 C0007133

Summaries for Papillary Carcinoma

Disease Ontology : 12 A carcinoma that is derives from epithelial cells with finger like projections.

MalaCards based summary : Papillary Carcinoma, also known as carcinoma, papillary, is related to renal cell carcinoma, papillary, 1 and primary peritoneal carcinoma. An important gene associated with Papillary Carcinoma is TG (Thyroglobulin), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs BCG vaccine and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Papillary Carcinoma

Diseases related to Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 366)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, papillary, 1 33.8 BRAF ERBB2 KRT7 MET PAX8
2 primary peritoneal carcinoma 33.2 ERBB2 PGR RET
3 thyroid cancer, nonmedullary, 1 32.8 BRAF NCOA4 NKX2-1
4 papillary transitional carcinoma 32.7 KRT20 KRT7
5 papillary serous adenocarcinoma 32.3 KRT20 KRT7 NKX2-1 PGR
6 renal cell carcinoma, nonpapillary 31.8 CDH1 KRT19 KRT20 KRT7 MET MUC1
7 thyroid cancer, nonmedullary, 2 30.5 BRAF CALCA KRT19 LGALS3 NKX2-1 PAX8
8 differentiated thyroid carcinoma 30.5 BRAF MET NCOA4 NKX2-1 PAX8 RET
9 thyroiditis 30.3 CALCA RET TG TPO TSHR
10 struma ovarii 30.1 BRAF NKX2-1 RET TG TSHR
11 suppurative thyroiditis 30.0 CALCA TG
12 mucoepidermoid carcinoma 30.0 CALCA ERBB2 KRT7 MUC1 TG
13 papillary adenoma 30.0 KRT7 NKX2-1
14 intracystic papillary adenoma 29.9 ERBB2 PGR
15 in situ carcinoma 29.9 CDH1 ERBB2 PGR
16 thyroid carcinoma, familial medullary 29.9 CALCA NKX2-1 RET TG
17 adenocarcinoma 29.9 BRAF CDH1 ERBB2 MUC1 RET
18 squamous cell carcinoma 29.8 BRAF CDH1 ERBB2 KRT19 MUC1
19 hyperthyroidism 29.8 TG TPO TSHR
20 cystic teratoma 29.7 KRT20 KRT7 NKX2-1
21 graves disease 1 29.7 TG TPO TSHR
22 subacute thyroiditis 29.7 TG TPO TSHR
23 dysgerminoma 29.7 KRT20 KRT7 MUC1
24 ductal carcinoma in situ 29.7 CDH1 ERBB2 MUC1 PGR
25 large cell neuroendocrine carcinoma 29.6 KRT20 KRT7 NKX2-1
26 cystadenocarcinoma 29.6 ERBB2 KRT7 MUC1 PGR
27 goiter 29.6 CALCA LGALS3 NKX2-1 PAX8 TG TPO
28 malignant struma ovarii 29.5 KRT19 LGALS3 NCOA4 NKX2-1 RET TG
29 transitional cell carcinoma 29.5 BRAF CDH1 ERBB2 KRT20 KRT7
30 multinodular goiter 29.5 CALCA NKX2-1 PAX8 TG TPO TSHR
31 thymus cancer 29.5 KRT7 MUC1 NKX2-1 PAX8
32 endosalpingiosis 29.5 KRT7 MUC1 PAX8 PGR
33 adenocarcinoma in situ 29.5 KRT20 KRT7 PAX8
34 follicular adenoma 29.4 CALCA KRT19 LGALS3 NKX2-1 PAX8 RET
35 hypothyroidism 29.4 CALCA NKX2-1 PAX8 RET TG TPO
36 lymphoepithelioma-like carcinoma 29.3 CDH1 KRT20 KRT7 MUC1
37 neonatal hypothyroidism 29.3 PAX8 TG TPO TSHR
38 clear cell renal cell carcinoma 29.2 CDH1 KRT7 MET MUC1 PAX8
39 sarcoma, synovial 29.2 CDH1 KRT19 KRT7 MET MUC1
40 ovarian cancer 1 29.2 CDH1 ERBB2 KRT7 PAX8
41 ovarian cancer 29.1 BRAF CDH1 CLDN3 ERBB2 KRT7 MUC1
42 congenital hypothyroidism 29.1 NKX2-1 PAX8 TG TPO TSHR
43 hashimoto thyroiditis 29.1 BRAF CALCA KRT19 LGALS3 RET TG
44 papillary adenocarcinoma 29.0 CDH1 ERBB2 KRT7 MUC1 NKX2-1 PGR
45 anaplastic thyroid cancer 29.0 BRAF CDH1 MET NKX2-1 PAX8 TG
46 lung cancer 29.0 BRAF CDH1 ERBB2 KRT19 KRT20 KRT7
47 adenoid cystic carcinoma 28.8 CDH1 ERBB2 KRT19 KRT20 KRT7 MUC1
48 cholangiocarcinoma 28.6 BRAF CDH1 ERBB2 KRT19 KRT20 KRT7
49 thyroid cancer 28.2 BRAF CALCA CDH1 KRT19 LGALS3 MET
50 breast papillary carcinoma 12.3

Graphical network of the top 20 diseases related to Papillary Carcinoma:



Diseases related to Papillary Carcinoma

Symptoms & Phenotypes for Papillary Carcinoma

MGI Mouse Phenotypes related to Papillary Carcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 BRAF CDH1 ERBB2 KRT19 KRT7 LGALS3
2 homeostasis/metabolism MP:0005376 10.3 BRAF CDH1 ERBB2 KRT7 LGALS3 MET
3 endocrine/exocrine gland MP:0005379 10.27 BRAF CDH1 ERBB2 KRT19 MET NKX2-1
4 growth/size/body region MP:0005378 10.26 BRAF CDH1 ERBB2 KRT19 LGALS3 MET
5 cardiovascular system MP:0005385 10.25 BRAF CDH1 ERBB2 KRT19 LGALS3 MET
6 digestive/alimentary MP:0005381 10.18 BRAF CDH1 ERBB2 KRT19 LGALS3 MET
7 mortality/aging MP:0010768 10.18 BRAF CDH1 ERBB2 KRT19 LGALS3 MET
8 embryo MP:0005380 10.11 BRAF CDH1 ERBB2 KRT19 MET PAX8
9 limbs/digits/tail MP:0005371 10.09 BRAF ERBB2 MET PAX8 PGR RET
10 neoplasm MP:0002006 10.07 BRAF CDH1 ERBB2 KRT19 LGALS3 MET
11 nervous system MP:0003631 10.02 BRAF ERBB2 KRT19 LGALS3 MET NKX2-1
12 normal MP:0002873 9.81 BRAF CDH1 ERBB2 KRT19 MET NKX2-1
13 no phenotypic analysis MP:0003012 9.8 CDH1 KRT19 MET NKX2-1 PAX8 PGR
14 reproductive system MP:0005389 9.7 BRAF CDH1 CLDN3 ERBB2 KRT19 LGALS3
15 skeleton MP:0005390 9.32 BRAF ERBB2 KRT19 LGALS3 NKX2-1 PAX8

Drugs & Therapeutics for Papillary Carcinoma

Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Investigational Phase 3
2 Vaccines Phase 3
3 Immunologic Factors Phase 3,Phase 2,Phase 1
4 Adjuvants, Immunologic Phase 3
5 Antibiotics, Antitubercular Phase 3,Phase 2
6 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
7 Alkylating Agents Phase 3,Phase 2
8 Nucleic Acid Synthesis Inhibitors Phase 3
9 Mitomycins Phase 3
10
Everolimus Approved Phase 2 159351-69-6 6442177
11
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Iodine Approved, Investigational Phase 2,Phase 1,Not Applicable 7553-56-2 807
14
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
15
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
16
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
17
Lenvatinib Approved, Investigational Phase 2 417716-92-8
18
Pembrolizumab Approved Phase 2 1374853-91-4
19
Trametinib Approved Phase 2 871700-17-3 11707110
20
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
21
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
22
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
23
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
24 Hormones Phase 2,Not Applicable
25 Radiopharmaceuticals Phase 1, Phase 2,Phase 2
26 Fluorodeoxyglucose F18 Phase 1, Phase 2,Phase 2
27 Immunosuppressive Agents Phase 2,Phase 1
28 Antifungal Agents Phase 2
29 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
30 Bendamustine Hydrochloride Phase 2
31 Antineoplastic Agents, Alkylating Phase 2
32 cadexomer iodine Phase 2,Phase 1,Not Applicable
33 Antibodies Phase 2
34 Mitogens Phase 2
35 Deoxyglucose Phase 2
36 Immunoglobulins Phase 2
37 Endothelial Growth Factors Phase 2
38 Fluorides Phase 2
39
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
40 Angiogenesis Inhibitors Phase 2,Phase 1
41 Angiogenesis Modulating Agents Phase 2,Phase 1
42 Protein Kinase Inhibitors Phase 2,Phase 1
43 Micronutrients Phase 2,Not Applicable
44 Anti-Infective Agents, Local Phase 2,Not Applicable
45 Trace Elements Phase 2,Not Applicable
46 Albumin-Bound Paclitaxel Phase 1, Phase 2,Phase 2
47 Antimitotic Agents Phase 1, Phase 2,Phase 2
48 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2
49 Antibodies, Monoclonal Phase 2
50
Cisplatin Approved Phase 1 15663-27-1 2767 441203 84093

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
4 Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. Recruiting NCT03335059 Phase 3
5 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
6 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2 RAD001
7 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Completed NCT00688623 Phase 2 Everolimus
8 Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Completed NCT00867503 Phase 2 Bendamustine HCL
9 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2 Selumetinib
10 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
11 pazopanib_NCRCC,Ph2 STUDY Completed NCT01538238 Phase 2 pazopanib
12 Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer Completed NCT00425386 Phase 2 erlotinib hydrochloride;sunitinib malate
13 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
14 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
15 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
16 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
17 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
18 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
19 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
20 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Active, not recruiting NCT01367002 Phase 2 Carboplatin/Paclitaxel;Trastuzumab
21 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
22 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
23 Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Not yet recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
24 Toremifene in Treating Patients With Ovarian Cancer Withdrawn NCT00003865 Phase 2 toremifene
25 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
26 Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors Terminated NCT02313012 Phase 1 CC-90003
27 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399 Not Applicable
28 Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid Unknown status NCT00984191 Not Applicable
29 Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy Unknown status NCT02768753
30 Influence of Thyroid Hormones on the Woundhealing Process Unknown status NCT00929318 Not Applicable
31 APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. Completed NCT02323724
32 Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients Completed NCT01150318 Not Applicable Administration of 131 iodine
33 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study Completed NCT01927887 Not Applicable Ferumoxytol
34 Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors Completed NCT00001668
35 PACE4 in Thyroid Cancer Completed NCT03160482
36 A Gene Hunting Study for Familial Papillary Thyroid Cancer Recruiting NCT02776969
37 the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma Not yet recruiting NCT03813706 Not Applicable

Search NIH Clinical Center for Papillary Carcinoma

Cochrane evidence based reviews: carcinoma, papillary

Genetic Tests for Papillary Carcinoma

Anatomical Context for Papillary Carcinoma

MalaCards organs/tissues related to Papillary Carcinoma:

41
Thyroid, Lymph Node, Breast, Ovary, Lung, Kidney, Thymus

Publications for Papillary Carcinoma

Articles related to Papillary Carcinoma:

(show top 50) (show all 1070)
# Title Authors Year
1
Coexistent cutaneous myeloid sarcoma in a patient with invasive papillary carcinoma of thyroid - A rare presentation. ( 29855456 )
2018
2
Solid Papillary Carcinoma of the Breast: Magnetic Resonance Mammography, Digital Mammography, and Ultrasound Findings. ( 29613993 )
2018
3
Papillary carcinoma in thyroglossal duct cyst: Diagnosis by fine-needle aspiration cytology and immunocytochemistry. ( 29737627 )
2018
4
Papillary Carcinoma of Thyroid with Nasal Cavity Metastases: A Case Report. ( 29398758 )
2018
5
Paratesticular Serous Papillary Carcinoma of High Grade and Malignant Potential: A Rare Case with a Role for Adjuvant Therapy. ( 29662727 )
2018
6
Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases. ( 29785016 )
2018
7
Intracystic papillary carcinoma of the male breast: a case report. ( 29361955 )
2018
8
Mammographic and ultrasound findings in poroid hidradenoma of the breast mimicking intraductal papilloma and papillary carcinoma: A case report. ( 29924021 )
2018
9
Preoperative injection of carbon nanoparticles is beneficial to the patients with thyroid papillary carcinoma: From a prospective study of 102 cases. ( 29979421 )
2018
10
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease. ( 29887709 )
2018
11
Magnetic Resonance Imaging Features of Breast Encapsulated Papillary Carcinoma. ( 29787497 )
2018
12
Encapsulated papillary carcinoma of the breast: A clinicopathological study of 49 cases. ( 29731165 )
2018
13
Papillary Carcinoma of Stensen's Duct with Intestinal Differentiation. ( 29774486 )
2018
14
Apocrine Encapsulated Papillary Carcinoma of the Breast: The First Reported Case with an Infiltrative Component. ( 29963120 )
2018
15
LncRNA BISPR promotes the progression of thyroid papillary carcinoma by regulating miR-21-5p. ( 29856242 )
2018
16
Early Local Recurrence in a Patient With Encapsulated Papillary Carcinoma of the Breast. ( 29803324 )
2018
17
Acute suppurative thyroiditis caused by thyroid papillary carcinoma in the right thyroid lobe of a healthy woman. ( 29785209 )
2018
18
Papillary Carcinoma Thyroid Presenting as Huge Scalp Metastases. ( 29643664 )
2018
19
Transoral videolaryngoscopic surgery for papillary carcinoma arising in lingual thyroid. ( 29776698 )
2018
20
Diagnosing between papillary carcinoma and reactive papillary changes in an infarcted thyroid nodule after fine needle aspiration and accompanied by a synchronous brain stem astrocytoma. ( 29607437 )
2018
21
Primary thyroid biphasic synovial sarcoma and synchronous papillary carcinoma: report of a remarkable case. ( 30546147 )
2018
22
Encapsulated Papillary Carcinoma in A Man with Gynecomastia: Ultrasonography, Mammography and Magnetic Resonance Imaging Features with Pathologic Correlation. ( 29774323 )
2018
23
Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast. ( 30455948 )
2018
24
Papillary carcinoma of thyroid in a thyroglossal cyst. ( 29491616 )
2018
25
False-positive radioiodine accumulation in a huge pelvic mass after thyroidectomy for papillary carcinoma, a case report from Syria. ( 29511526 )
2018
26
Ubiquitin Immunostaining in Thyroid Neoplasms Marks True Intranuclear Cytoplasmic Pseudoinclusions and May Help Differentiate Papillary Carcinoma from NIFTP. ( 29512025 )
2018
27
Intracystic papillary carcinoma of the breast: Experience of a major Chinese cancer center. ( 29526557 )
2018
28
Invasive Solid Papillary Carcinoma of the Nipple With Pagetoid Extension and Nodal Metastasis. ( 29580118 )
2018
29
Invasive Thyroglossal Duct Cyst Papillary Carcinoma: A Case Report and Review of the Literature. ( 29950556 )
2018
30
High-grade encapsulated papillary carcinoma of the breast is clinicopathologically distinct from low/intermediate-grade neoplasms in Chinese patients. ( 30004109 )
2018
31
Imaging of Intracystic Papillary Carcinoma. ( 30072190 )
2018
32
miR-497 inhibited proliferation, migration and invasion of thyroid papillary carcinoma cells by negatively regulating YAP1 expression. ( 30127619 )
2018
33
Hot and malignant - a case of invasive papillary carcinoma in hyperthyroid patient with hot nodules. ( 30181830 )
2018
34
Diagnosis, treatment, and outcomes of encapsulated papillary carcinoma: a single institution experience. ( 30210240 )
2018
35
Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma: Molecular Characterization by Next-Generation Sequencing and Histopathological Comparison With Tall Cell Papillary Carcinoma of Thyroid. ( 30227763 )
2018
36
Genetic variations in TAS2R3 and TAS2R4 bitterness receptors modify papillary carcinoma risk and thyroid function in Korean females. ( 30301923 )
2018
37
Breast Tumours Resembling the Tall Cell Variant of Thyroid Papillary Carcinoma: Are They Part of the Papillary Carcinoma Spectrum or a Distinct Entity? ( 30308500 )
2018
38
Inguinal Lymph Node Metastasis of a Primary Serous Papillary Carcinoma of the Peritoneum One Year after CRS and HIPEC. ( 30345290 )
2018
39
Positive effect of RORγt on the prognosis of thyroid papillary carcinoma patients combined with Hashimoto's thyroiditis. ( 30416647 )
2018
40
Clinical features of poorly differentiated thyroid papillary carcinoma. ( 30466760 )
2018
41
Evaluation of the presence of Epstein-Barr virus (EBV) in Iranian patients with thyroid papillary carcinoma. ( 28554750 )
2017
42
Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory BehAset disease uveitis and concomitant bladder papillary carcinoma. ( 28891187 )
2017
43
Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze. ( 29150742 )
2017
44
Anaplastic Spindle Cell Squamous Carcinoma Arising from Tall Cell Variant Papillary Carcinoma of the Thyroid Gland: A Case Report and Review of the Literature. ( 28484653 )
2017
45
Rosettes in papillary carcinoma of thyroid: A rare cytomorphological indicator of aggressive variants. ( 29165889 )
2017
46
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma. ( 28521457 )
2017
47
Hashimoto's thyroiditis - an independent risk factor for papillary carcinoma. ( 28964693 )
2017
48
Papillary carcinoma in struma ovarii. ( 28251552 )
2017
49
An Indian Tertiary Care Hospital Scenario of Papillary Carcinoma of Thyroid. ( 28764174 )
2017
50
18F-FDG PET/CT of Papillary Carcinoma in a Lateral Thyroglossal Duct Cyst. ( 28525461 )
2017

Variations for Papillary Carcinoma

Expression for Papillary Carcinoma

Search GEO for disease gene expression data for Papillary Carcinoma.

Pathways for Papillary Carcinoma

GO Terms for Papillary Carcinoma

Cellular components related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 CLDN3 ERBB2 MET MUC1 RET TPO
2 receptor complex GO:0043235 8.92 ERBB2 MET RET TSHR

Biological processes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.91 BRAF ERBB2 LGALS3 MET PAX8 RET
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.67 BRAF ERBB2 MET RET
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.63 ERBB2 MET RET
4 MAPK cascade GO:0000165 9.62 BRAF ERBB2 MET RET
5 peptidyl-tyrosine phosphorylation GO:0018108 9.46 BRAF ERBB2 MET RET
6 hormone biosynthetic process GO:0042446 9.4 TG TPO
7 entry of bacterium into host cell GO:0035635 9.26 CDH1 MET
8 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 PAX8 TSHR
9 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG

Molecular functions related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 BRAF CALCA CDH1 CLDN3 ERBB2 MET
2 transmembrane signaling receptor activity GO:0004888 9.62 CLDN3 ERBB2 MET RET
3 protein phosphatase binding GO:0019903 9.54 ERBB2 LGALS3 MET
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 ERBB2 MET RET
5 protein tyrosine kinase activity GO:0004713 9.26 BRAF ERBB2 MET RET
6 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....